Serum Mac‐2‐binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir‐treated chronic hepatitis B patients
| Autor: | Teresa Lok-Yee Hui, James Fung, Justin Hei-Chun Ma, Wai-Kay Seto, Elvis W.P. To, Man-Fung Yuen, Lung-Yi Mak, Michael Ko, Danny Ka-Ho Wong, Ching-Lung Lai |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Carcinoma Hepatocellular Guanine Time Factors Multivariate analysis Antiviral Agents Risk Assessment Gastroenterology 03 medical and health sciences Hepatitis B Chronic 0302 clinical medicine Antigens Neoplasm Risk Factors Internal medicine Biomarkers Tumor Humans Medicine Retrospective Studies Membrane Glycoproteins Hepatology business.industry Incidence Incidence (epidemiology) Liver Neoplasms Odds ratio Entecavir Middle Aged Hepatitis B medicine.disease digestive system diseases Confidence interval Treatment Outcome 030220 oncology & carcinogenesis Hepatocellular carcinoma Hong Kong Biomarker (medicine) Female 030211 gastroenterology & hepatology business Biomarkers medicine.drug |
| Zdroj: | Journal of Gastroenterology and Hepatology. 34:1817-1823 |
| ISSN: | 1440-1746 0815-9319 |
| DOI: | 10.1111/jgh.14637 |
| Popis: | Background and aim Hepatocellular carcinoma (HCC) can still develop in chronic hepatitis B (CHB) patients receiving antiviral treatment. Serum Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel marker for liver fibrosis. We investigated its role on incidence of HCC in entecavir (ETV)-treated CHB patients. Methods We identified HCC cases diagnosed at ≥ 1 year of ETV treatment. CHB patients without HCC (matched for age, gender, baseline hepatitis B virus-DNA, and duration of ETV treatment) were identified in approximately 1:2 ratio (HCC: non-HCC) for comparison. Serum samples were retrieved at baseline (initiation of ETV), 3, and 5 years of ETV for serum M2BPGi measurement (expressed in cut-off index [COI]). Results One hundred HCC cases were matched with 185 CHB patients without HCC (median age 56.7 years, 78.9% male, baseline hepatitis B virus-DNA 5.6 logIU/mL, and median follow-up 7.1 years). Median time from ETV initiation to incident HCC was 3.9 years. Serum M2BPGi levels were significantly higher in HCC cases compared with controls at baseline and year 3 (1.25 vs 0.98 [P = 0.004], 0.89 vs 0.74 [P = 0.018] COI, respectively). Multivariate analysis showed that baseline M2BPGi was the only independent factor associated with incident HCC (odds ratio 1.241, 95% confidence interval 1.039-1.482, P = 0.017). Using a cut-off value of 1.15 COI, the sensitivity, specificity, positive predictive value, and negative predictive value of baseline serum M2BPGi in cirrhotic patients to predict incident HCC were 90%, 53.8%, 69.6%, and 82.1%, respectively. Conclusions Baseline and 3-year serum M2BPGi may be useful to identify high risk patients on antiviral treatment for subsequent HCC development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text